来宝网 2024/12/11点击126次
InVivoMAb抗鼠TCRγ/δ,多功能体内实验专用抗体
V65单克隆抗体与大鼠γ/δTCR(γδT细胞受体)反应。γ/δTCR由胸腺、外周淋巴组织、肠上皮、表皮和腹膜中发现的T细胞亚群表达。表达γ/δTCR的T细胞的确切功能、配体和特异性尚不完全清楚。研究表明,这些细胞在MHC I类基因产物的背景下识别细菌配体和一些肿瘤细胞,并在细菌感染期间调节免疫反应中发挥作用。
艾美捷InVivoMAb抗鼠TCRγ/δ/InVivoMAb anti-rat TCR γ/δ:
货号:BE0414
同型:小鼠IgG1,κ
推荐同型对照:InVivoMAb小鼠IgG1同型对照,未知特异性
推荐稀释缓冲液:InVivoPure pH 7.0稀释缓冲液
偶联:未偶联。可通过BioXCell的抗体偶联服务进行偶联。
免疫原:大鼠T细胞母细胞
报告应用:体内γ/δ T细胞耗竭
流式细胞术
配方:PBS,pH 7.0
不含稳定剂或防腐剂
内毒素:<2EU/mg(<0.002EU/μg)
由LAL凝胶凝集试验确定
纯度:>95%
由SDS-PAGE确定
无菌性:0.2微米过滤
生产:在无动物设施中从细胞培养上清液中纯化
纯化:蛋白G
分子量:150 kDa
储存:抗体溶液应以原液浓度在4°C下储存。不要冷冻。
InVivoMAb抗鼠TCRγ/δ/InVivoMAb anti-rat TCR γ/δ文献引用:
Flow Cytometry
Ando T, Wu H, Watson D, Hirano T, Hirakata H, Fujishima M, Knight JF. (2001). "Infiltration of canonical Vgamma4/Vdelta1 gammadelta T cells in an adriamycin-induced progressive renal failure model" J Immunol 167(7):3740-5.
in vivo γ/δ T cell depletion
Jansson AM, Lorentzen JC, Bucht A. (2000). "CD8+ cells suppress oil-induced arthritis" Clin Exp Immunol 120(3):532-6.
Flow Cytometry
Knudsen E, Seierstad T, Vaage JT, Naper C, Benestad HB, Rolstad B, Maghazachi AA. (1997). "Cloning, functional activities and in vivo tissue distribution of rat NKR-P1+ TCR alpha beta + cells" Int Immunol 9(7):1043-51.
Kühnlein P, Park JH, Herrmann T, Elbe A, Hünig T. (1994). "Identification and characterization of rat gamma/delta T lymphocytes in peripheral lymphoid organs, small intestine, and skin with a monoclonal antibody to a constant determinant of the gamma/delta T cell receptor" J Immunol 153(3):979-86.
https://www.amyjet.com/products/BXC-BE0414-1mg.shtml
InVivoMAb抗大鼠TCRα/β,高效体内免疫调节和T细胞耗竭专用抗体
R73单克隆抗体与大鼠α/βTCR(α-βT细胞受体)的框架成分反应。α/βTCR由大多数外周T细胞、肠上皮淋巴细胞和胸腺细胞表达。据报道,R73抗体可以抑制实验性自身免疫性脑炎和佐剂性关节炎的发展。此外,R73治疗在移植领域得到了应用,并防止了心脏、皮肤、小肠、肾脏和角膜的同种异体排斥反应。
艾美捷InVivoMAb抗大鼠TCRα/β/InVivoMAb anti-rat TCR α/β:
货号:BE0413
同型:小鼠IgG1,κ
推荐同型对照:InVivoMAb小鼠IgG1同型对照,未知特异性
推荐稀释缓冲液:InVivoPure pH 7.0稀释缓冲液
偶联:未偶联。可通过BioXCell的抗体偶联服务进行偶联。
免疫原:大鼠T细胞母细胞和红细胞
报告应用:体内给药
配方:PBS,pH 7.0
不含稳定剂或防腐剂
内毒素:<2EU/mg(<0.002EU/μg)
由LAL凝胶凝集试验确定
纯度:>95%
由SDS-PAGE确定
无菌性:0.2微米过滤
生产:在无动物设施中从细胞培养上清液中纯化
纯化:蛋白G
分子量:150 kDa
储存:抗体溶液应以原液浓度在4°C下储存。不要冷冻。
InVivoMAb抗大鼠TCRα/β/InVivoMAb anti-rat TCR α/β文献引用:
in vivo administration
Jörns A, Ishikawa D, Teraoku H, Yoshimoto T, Wedekind D, Lenzen S. (2020). "Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes" BMC Med 18(1):33.
in vivo administration
Inoki T, Yamagami S, Sakai R, Isobe M, Tsuru T, Kawashima H. (2002). "Suppression of experimental autoimmune uveoretinitis by anti-alphabeta TCR monoclonal antibody" Jpn J Ophthalmol 46(5):518-24.
in vivo administration
Schorlemmer HU, Kanzy EJ, Kurrle R, Seiler FR. (1991). "Inhibitory effects of the anti-rat T-cell receptor (TCR) monoclonal antibody (MAb) R73 on various experimental autoimmune diseases" Agents Actions 34(1-2):161-4.
https://www.amyjet.com/products/BXC-BE0413-1mg.shtml
InVivoMAb抗大鼠IL-4高纯度、低内毒素,体内实验的选择
OX-81单克隆抗体与大鼠IL-4(白细胞介素-4)反应,IL-4是一种多功能14kDa细胞因子。IL-4主要由活化的Th2细胞和NK细胞表达,在较低水平上由肥大细胞和嗜碱性粒细胞表达。IL-4通过IL-4Rα发出信号。在受体结合时,IL-4刺激活化的B和T淋巴细胞增殖,以及B细胞分化为浆细胞。它还诱导B细胞类转换为IgE,上调MHC II类的产生,同时减少Th1细胞、巨噬细胞、IFNγ和树突状细胞IL-12的产生。与其他Th2相关细胞因子一样,IL-4参与了过敏性哮喘患者肺部观察到的气道炎症。OX-81抗体已被证明可以中和大鼠IL-4的生物活性。
艾美捷InVivoMAb抗大鼠IL-4/InVivoMAb anti-rat IL-4:
货号:BE0419
同型:小鼠IgG1,κ
推荐同型对照:InVivoMAb小鼠IgG1同型对照,未知特异性
推荐稀释缓冲液:InVivoPure pH 7.0稀释缓冲液
偶联:未偶联。可通过BioXCell的抗体偶联服务进行偶联。
免疫原:重组大鼠IL-4
报告应用:体内IL-4中和
酶联免疫吸附试验(ELISA)
流式细胞术
配方:PBS,pH 7.0
不含稳定剂或防腐剂
内毒素:<2EU/mg(<0.002EU/μg)
由LAL凝胶凝集试验确定
纯度:>95%
由SDS-PAGE确定
无菌性:0.2微米过滤
生产:在无动物设施中从细胞培养上清液中纯化
纯化:蛋白G
分子量:150 kDa
储存:抗体溶液应以原液浓度在4°C下储存。不要冷冻。
InVivoMAb抗大鼠IL-4/InVivoMAb anti-rat IL-4文献引用:
Flow Cytometry
Mitsuoka N, Iwagaki H, Ozaki M, Sheng SD, Sadamori H, Matsukawa H, Morimoto Y, Matsuoka J, Tanaka N, Yagi T. (2004). "The impact of portal infusion with donor-derived bone marrow cells and intracellular cytokine expression of graft-infiltrating lymphocytes on the graft survival in rat small bowel transplant model" Transpl Immunol 13(3):155-60.
ELISA
Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. (2002). "Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis" J Immunol 169(5):2685-93.
in vivo IL-4 neutralization
Tran GT, Carter N, He XY, Spicer TS, Plain KM, Nicolls M, Hall BM, Hodgkinson SJ. (2001). "Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4" Int Immunol 13(9):1109-20.
ELISA
Uchikawa R, Matsuda S, Arizono N. (2000). "Suppression of gamma interferon transcription and production by nematode excretory-secretory antigen during polyclonal stimulation of rat lymph node T cells" Infect Immun 68(11):6233-9.
https://www.amyjet.com/products/BXC-BE0419-1mg.shtml
InVivoMAb抗大鼠CTLA-4(CD152),高效中和CTLA-4,助力肿瘤免疫研究
OX-81单克隆抗体与大鼠IL-4(白细胞介素-4)反应,IL-4是一种多功能14kDa细胞因子。IL-4主要由活化的Th2细胞和NK细胞表达,在较低水平上由肥大细胞和嗜碱性粒细胞表达。IL-4通过IL-4Rα发出信号。在受体结合时,IL-4刺激活化的B和T淋巴细胞增殖,以及B细胞分化为浆细胞。它还诱导B细胞类转换为IgE,上调MHC II类的产生,同时减少Th1细胞、巨噬细胞、IFNγ和树突状细胞IL-12的产生。与其他Th2相关细胞因子一样,IL-4参与了过敏性哮喘患者肺部观察到的气道炎症。OX-81抗体已被证明可以中和大鼠IL-4的生物活性。
艾美捷InVivoMAb抗大鼠CTLA-4(CD152)/InVivoMAb anti-rat CTLA-4 (CD152) :
货号:BE0424
同型:小鼠IgG1,κ
推荐同型对照:InVivoMAb小鼠IgG1同型对照,未知特异性
推荐稀释缓冲液:InVivoPure pH 7.0稀释缓冲液
免疫原:纯化的大鼠CTLA-4hIg融合蛋白
报告应用:体外CTLA-4中和
流式细胞术
配方:PBS,pH 7.0
不含稳定剂或防腐剂
内毒素:<2EU/mg(<0.002EU/μg)
由LAL凝胶凝集试验确定
纯度:>95%
由SDS-PAGE确定
无菌性:0.2微米过滤
生产:在无动物设施中从细胞培养上清液中纯化
纯化:蛋白G
分子量:150 kDa
储存:抗体溶液应以原液浓度在4°C下储存。不要冷冻。
InVivoMAb抗大鼠CTLA-4(CD152)/InVivoMAb anti-rat CTLA-4 (CD152) 文献参考:
in vitro CTLA-4 neutralization
Takatsuka N, Hasegawa A, Takamori A, Shimizu Y, Kato H, Ohashi T, Amagasa T, Masuda T, Kannagi M. (2009). "Induction of IL-10- and IFN-gamma-producing T-cell responses by autoreactive T-cells expressing human T-cell leukemia virus type I Tax" Int Immunol 21(9):1089-100.
Flow Cytometry, in vitro CTLA-4 neutralization
Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hünig T, Kerkau T, Gold R. (2005). "Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis" J Exp Med 202(3):445-55.
Flow Cytometry, in vitro CTLA-4 neutralization
Lin CH, Hünig T. (2003). "Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist" Eur J Immunol 33(3):626-38.
Flow Cytometry
Elflein K, Rodriguez-Palmero M, Kerkau T, Hünig T. (2003). "Rapid recovery from T lymphopenia by CD28 superagonist therapy" Blood 102(5):1764-70.
https://www.amyjet.com/products/BXC-BE0424-1mg.shtml
InVivoMAb抗大鼠CD8α,助力细胞毒性T细胞反应的研究
OX-8单克隆抗体与大鼠CD8α的铰链样膜近端结构域发生反应。CD8抗原是一种跨膜糖蛋白,充当T细胞受体(TCR)的共受体。与TCR一样,CD8与抗原呈递细胞(APC)显示的I类MHC分子结合。CD8主要在细胞毒性T细胞的表面表达,但也可以在胸腺细胞、自然杀伤细胞和一些树突状细胞亚群上发现。CD8最常见的是由一条CD8α和一条CD8β链组成的异二聚体,但它也可以由两条CD8α链组成的同二聚体存在。CD8α和CD8β链与免疫球蛋白可变轻链具有显著同源性。据报道,OX-8抗体在体内使用时表现出CD8 T细胞耗竭活性。
艾美捷InVivoMAb抗大鼠CD8α/InVivoMAb anti-rat CD8α :
货号:BE0415
同型:小鼠IgG1,κ
推荐同型对照:InVivoMAb小鼠IgG1同型对照,未知特异性
推荐稀释缓冲液:InVivoPure pH 7.0稀释缓冲液
免疫原:纯化的大鼠CTLA-4hIg融合蛋白
报告应用:体外CTLA-4中和
流式细胞术
配方:PBS,pH 7.0
不含稳定剂或防腐剂
内毒素:<2EU/mg(<0.002EU/μg)
由LAL凝胶凝集试验确定
纯度:>95%
由SDS-PAGE确定
无菌性:0.2微米过滤
生产:在无动物设施中从细胞培养上清液中纯化
纯化:蛋白G
分子量:150 kDa
储存:抗体溶液应以原液浓度在4°C下储存。不要冷冻。
InVivoMAb抗大鼠CD8α/InVivoMAb anti-rat CD8α文献参考:
in vivo CD8+ T cell depletion, Flow Cytometry
Hartlage AS, Murthy S, Kumar A, Trivedi S, Dravid P, Sharma H, Walker CM, Kapoor A. (2019). "Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection" Nat Commun 10(1):1113.
Immunohistochemistry (paraffin)
Shibata S, Shinozaki N, Suganami A, Ikegami S, Kinoshita Y, Hasegawa R, Kentaro H, Okamoto Y, Aoki I, Tamura Y, Iwadate Y. (2019). "Photo-immune therapy with liposomally formulated phospholipid-conjugated indocyanine green induces specific antitumor responses with heat shock protein-70 expression in a glioblastoma model" Oncotarget 10(2):175-183.
in vivo CD8+ T cell depletion
Nuccitelli R, Berridge JC, Mallon Z, Kreis M, Athos B, Nuccitelli P. (2015). "Nanoelectroablation of Murine Tumors Triggers a CD8-Dependent Inhibition of Secondary Tumor Growth" PLoS One 10(7):e0134364.
Immunohistochemistry (frozen)
Wallgren AC, Karlsson-Parra A, Korsgren O. (1995). "The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte" Transplantation 60(6):594-601.
https://www.amyjet.com/products/BXC-BE0415-1mg.shtml
InVivoMAb抗大鼠CD4,无动物成分生产,高纯度免疫学研究抗体
W3/25单克隆抗体与大鼠CD4发生反应。CD4是免疫球蛋白超家族的55 kDa I型膜糖蛋白,作为细胞表面受体蛋白,它充当抗原呈递细胞(APC)显示的II类MHC分子的共受体(与TCR)。CD4由大多数胸腺细胞、辅助T细胞、NK-T细胞亚群表达,由树突状细胞和巨噬细胞弱表达。CD4在T细胞的发育中起着重要作用,是成熟T细胞最佳功能所必需的。克隆W3/25被用作“辅助性T细胞标记物”。克隆W3/25是一种不完全的单克隆抗体,但已被证明在体外中和CD4。几项体外研究还表明,W3/25单克隆抗体通过下调淋巴细胞表面的CD4分子来抑制CD4+T细胞活化。W3/25单抗还在MLR实验中抑制抗原诱导的T细胞增殖和IL2的产生。在预防性和实验性治疗性体内研究中,该抗体已被广泛用于调节实验性变态反应性脑脊髓炎(EAE)、佐剂性关节炎等疾病相关和机制参数。
艾美捷InVivoMAb抗大鼠CD4/InVivoMAb anti-rat CD4:
货号:BE0439
同型:小鼠IgG1,κ
推荐同型对照:InVivoMAb大鼠IgG2b同型对照,抗血蓝蛋白
推荐稀释缓冲液:InVivoPure pH 7.0稀释缓冲液
报告应用:体内下调表面CD4
体外中和CD4
流式细胞术
石蜡切片免疫组化
冰冻切片免疫组化
配方:PBS,pH 7.0
不含稳定剂或防腐剂
内毒素:<2EU/mg(<0.002EU/μg)
由LAL凝胶凝集试验确定
纯度:>95%
由SDS-PAGE确定
无菌性:0.2微米过滤
生产:在无动物设施中从细胞培养上清液中纯化
纯化:蛋白G
分子量:150 kDa
储存:抗体溶液应以原液浓度在4°C下储存。不要冷冻。
推荐同型对照:
InVivoMAb大鼠IgG2b同型对照,抗血蓝蛋白
推荐稀释缓冲液:
InVivoPure pH 7.0稀释缓冲液
InVivoMAb抗大鼠CD4/InVivoMAb anti-rat CD4文献参考:
in vivo down-regulation of surface CD4, Flow Cytometry
Acroute DV, Lafitte S, Dive D, Khalife J, Pierrot C. (2010). "A role for CD4+ and CD8+ cells and not for CD25+ cells in the control of Plasmodium berghei Anka blood stage parasites in rats" Parasite 10.1051/parasite/2010171053.
Immunohistochemistry (frozen)
Wu Z, Toh K, Nagata K, Kukita T, Iijima T. (2004). "Effect of the resection of the sciatic nerve on the Th1/Th2 balance in the synovia of the ankle joint of adjuvant arthritic rats" Histochem Cell Biol 121(2):141-7.
in vivo down-regulation of surface CD4
Thullen TD, Ashbaugh AD, Daly KR, Linke MJ, Steele PE, Walzer PD. (2003). "New rat model of Pneumocystis pneumonia induced by anti-CD4(+) T-lymphocyte antibodies" Infect Immun 10.1128/IAI.71.11.6292-6297.2003.
in vivo down-regulation of surface CD4, Flow Cytometry
Pohlers D, Schmidt-Weber CB, Franch A, Kuhlmann J, Bräuer R, Emmrich F, Kinne RW. (2002). "Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kappaB binding activity and TNF-alpha secretion of T cells" Arthritis Res 10.1186/ar404.
https://www.amyjet.com/products/BXC-BE0439-1mg.shtml
InVivoMAb抗大鼠CD28,高纯度体内实验专用抗体
JJ316单克隆抗体与大鼠CD28反应,CD28是一种45kDa的共刺激受体,也是Ig超家族的成员。CD28由胸腺细胞、大多数外周T细胞和NK细胞表达。CD28是CD80(B7-1)和CD86(B7-2)的受体。通过CD28的信号传导增强IL-2和IL-2受体的表达以及CD3激活的T细胞的细胞毒性。与JJ319不同,JJ319是一种“传统”的CD28特异性单克隆抗体,在体外共刺激抗TCR引发的增殖,JJ316是一种CD28“超促性腺激素”抗体,在体内外诱导多克隆T细胞增殖,不需要TCR连接。
艾美捷InVivoMAb抗大鼠CD28/InVivoMAb anti-rat CD28:
货号:BE0418
同型:小鼠IgG1,κ
推荐同型对照:InVivoMAb小鼠IgG1同型对照,未知特异性
推荐稀释缓冲液:InVivoPure pH 7.0稀释缓冲液
偶联:未偶联。可通过BioXCell的抗体偶联服务进行偶联。
免疫原:转染大鼠CD28基因的BALB/c小鼠A2OJ细胞系
报告应用:体内T细胞刺激/激活
配方:PBS,pH 7.0
不含稳定剂或防腐剂
内毒素:<2EU/mg(<0.002EU/μg)
由LAL凝胶凝集试验确定
纯度:>95%
由SDS-PAGE确定
无菌性:0.2微米过滤
生产:在无动物设施中从细胞培养上清液中纯化
纯化:蛋白G
分子量:150 kDa
储存:抗体溶液应以原液浓度在4°C下储存。不要冷冻。
InVivoMAb抗大鼠CD28/InVivoMAb anti-rat CD28文献参考:
in vivo T cell stimulation/activation
Takabatake Y, Li XK, Mizui M, Miyasato K, Matsui I, Kawada N, Imai E, Hünig T, Takahara S, Wada T, Furuichi K, Rakugi H, Isaka Y. (2011). "A superagonistic monoclonal antibody for CD28 ameliorates crescentic glomerulonephritis in wistar-kyoto rats" Mol Med 17(7-8):686-96.
in vivo T cell stimulation/activation
Wang S, Liu J, Wang M, Zhang J, Wang Z. (2010). "Treatment and prevention of experimental autoimmune myocarditis with CD28 superagonists" Cardiology 115(2):107-13.
in vivo T cell stimulation/activation
Müller N, van den Brandt J, Odoardi F, Tischner D, Herath J, Flügel A, Reichardt HM. (2008). "A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats" J Clin Invest 118(4):1405-16.
in vivo T cell stimulation/activation
Rodríguez-Palmero M, Franch A, Castell M, Pelegrí C, Pérez-Cano FJ, Kleinschnitz C, Stoll G, Hünig T, Castellote C. (2006). "Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody" J Rheumatol 33(1):110-8.
https://www.amyjet.com/products/BXC-BE0418-1mg.shtml
InVivoMAb抗大鼠CD2/InVivoMAb anti-rat CD2,流式细胞术和免疫组化应用的多功能抗体
OX-34单克隆抗体与大鼠CD2反应,CD2是一种45-58kD的I型跨膜糖蛋白,也称为LFA-2、T11或Ly37。CD2是Ig超家族的成员。CD2由外周血淋巴细胞、胸腺细胞、形成E-玫瑰花结的所有T细胞和NK细胞的一个子集表达。CD2作为一种粘附受体,与CD58结合,导致CD2阳性T细胞和NK细胞的激活,并调节其细胞溶解活性。OX-34抗体已被证明可以阻断CD2与CD48的结合,并减轻大鼠已建立的佐剂性关节炎。
艾美捷InVivoMAb抗大鼠CD2/InVivoMAb anti-rat CD2:
货号:BE0417
同型:小鼠IgG2a,κ
推荐同型对照:InVivoMAb小鼠IgG2a同型对照,未知特异性
推荐稀释缓冲液:InVivoPure pH 7.0稀释缓冲液
偶联:未偶联。可通过BioXCell的抗体偶联服务进行偶联。
免疫原:大鼠T细胞母细胞
报告应用:体内CD2阻断
体外CD2阻断
西方印迹
配方:PBS,pH 7.0
不含稳定剂或防腐剂
内毒素:<2EU/mg(<0.002EU/μg)
由LAL凝胶凝集试验确定
纯度:>95%
由SDS-PAGE确定
无菌性:0.2微米过滤
生产:在无动物设施中从细胞培养上清液中纯化
纯化:蛋白G
分子量:150 kDa
储存:抗体溶液应以原液浓度在4°C下储存。不要冷冻。
InVivoMAb抗大鼠CD2/InVivoMAb anti-rat CD2文献参考:
in vivo CD2 blockade
Hoffmann JC, Herklotz C, Zeidler H, Bayer B, Westermann J. (1997). "Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 down-modulation" Clin Exp Immunol 110(1):63-71.
in vivo CD2 blockade
Hoffmann JC, Herklotz C, Zeidler H, Bayer B, Rosenthal H, Westermann J. (1997). "Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34" Ann Rheum Dis 56(12):716-22.
Western Blot
He Q, Beyers AD, Barclay AN, Williams AF. (1988). "A role in transmembrane signaling for the cytoplasmic domain of the CD2 T lymphocyte surface antigen" Cell 54(7):979-84.
in vitro CD2 blockade
Seaman WE, Eriksson E, Dobrow R, Imboden JB. (1987). "Inositol trisphosphate is generated by a rat natural killer cell tumor in response to target cells or to crosslinked monoclonal antibody OX-34: possible signaling role for the OX-34 determinant during activation by target cells" Proc Natl Acad Sci U S A 84(12):4239-43.
https://www.amyjet.com/products/BXC-BE0417-1mg.shtml